The evaluation of the efficacy and safety of nifekalan hydrochloride for injection in patients with electric storm

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027499

Enrollment

Unknown

Registered

2019-11-16

Start date

2016-03-01

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrhythmia electrical storm

Interventions

Case series:Nifekaran hydrochloride was given for injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: VT/VF occurred within 24h for >=3 times in patients who clearly needed electrocardiography or electrodefibrillation treatment; For patients with ICD implantation, discharge >=3 times within 24 hours; Patients with organic heart disease; Aged >=18 years male and female.

Exclusion criteria

Exclusion criteria: Patients with prolonged QT interval pleomorphic ventricular velocity and QTc interval exceeding 500ms before administration; Patients with torsional ventricular velocity at the tip (Tdp); Brugada syndrome; Patients with conduction dysfunction; Hypertrophic cardiomyopathy (HCM); Pregnant or lactating women; Patients who were considered unfit for the study by other researchers.

Design outcomes

Primary

Measure	Time frame
efficiency;	—

Countries

China

Contacts

Public ContactLiu Chengwei

Wuhan Asian Heart Hospital

whlcw60@126.com+86 18627077188

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026